Mindfulness-based interventions (MBIs) are beneficial for patients with coronary heart disease (CHD) in reducing perceived stress, depression and anxiety, as shown by evidence in a systematic review, which was presented at the recent European Society of Cardiology (ESC) Asia Congress 2019 in Singapore.
Emotion dysregulation during early schizophrenia spectrum disorder (SSD) appears to be linked to different cognitive risk factors which, in turn, compound depressive symptoms, according to a recent Singapore study.
Anaemia diagnosed earlier in pregnancy is associated with increased risk of development of autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and particularly intellectual disability (ID) in the offspring, according to results of a recent study.
A study of 74 Swedish twins and triplets discordant for attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and other neurodevelopmental diagnoses identified a consistent reduction in regularity and complexity of cobalt, lead and vanadium cycles in individuals with ADHD.
Women who show symptoms of postpartum depression in the first or sixth month after delivery tend to encounter difficulty caring for their infants, a recent study suggests. Left untreated, the mood disorder can prevent the formation of a critical bond between mother and child.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.